The tissue is the issue: Personalized medicine for non-small cell lung cancer

Fred R. Hirsch; Murry W. Wynes; David R Gandara; Paul A. Bunn

doi:10.1158/1078-0432.CCR-10-2005

The tissue is the issue: Personalized medicine for non-small cell lung cancer

Fred R. Hirsch, Murry W. Wynes, David R Gandara, Paul A. Bunn

Hematology and Oncology

Research output: Contribution to journal › Article

59 Scopus citations

Abstract

The development of molecular markers is crucial for improving therapy in advanced non-small cell lung cancer (NSCLC). Here, we review perspectives of biomarker-driven personalized therapy in NSCLC, with particular reference to the detection of EML4-ALK gene rearrangements. Different molecular assays, validation, and clinical application to different types of tissue specimens are discussed.

Original language	English (US)
Pages (from-to)	4909-4911
Number of pages	3
Journal	Clinical Cancer Research
Volume	16
Issue number	20
DOIs	https://doi.org/10.1158/1078-0432.CCR-10-2005
State	Published - Oct 15 2010

ASJC Scopus subject areas

Cancer Research
Oncology

Access to Document

10.1158/1078-0432.CCR-10-2005

Fingerprint Dive into the research topics of 'The tissue is the issue: Personalized medicine for non-small cell lung cancer'. Together they form a unique fingerprint.

Cite this

Hirsch, F. R., Wynes, M. W., Gandara, D. R., & Bunn, P. A. (2010). The tissue is the issue: Personalized medicine for non-small cell lung cancer. Clinical Cancer Research, 16(20), 4909-4911. https://doi.org/10.1158/1078-0432.CCR-10-2005

@article{e9fef3988ea84a8984ec09c7eb56ec67,

title = "The tissue is the issue: Personalized medicine for non-small cell lung cancer",

abstract = "The development of molecular markers is crucial for improving therapy in advanced non-small cell lung cancer (NSCLC). Here, we review perspectives of biomarker-driven personalized therapy in NSCLC, with particular reference to the detection of EML4-ALK gene rearrangements. Different molecular assays, validation, and clinical application to different types of tissue specimens are discussed.",

author = "Hirsch, {Fred R.} and Wynes, {Murry W.} and Gandara, {David R} and Bunn, {Paul A.}",

year = "2010",

month = oct,

day = "15",

doi = "10.1158/1078-0432.CCR-10-2005",

language = "English (US)",

volume = "16",

pages = "4909--4911",

journal = "Clinical Cancer Research",

issn = "1078-0432",

publisher = "American Association for Cancer Research Inc.",

number = "20",

}

TY - JOUR

T1 - The tissue is the issue

T2 - Personalized medicine for non-small cell lung cancer

AU - Hirsch, Fred R.

AU - Wynes, Murry W.

AU - Gandara, David R

AU - Bunn, Paul A.

PY - 2010/10/15

Y1 - 2010/10/15

N2 - The development of molecular markers is crucial for improving therapy in advanced non-small cell lung cancer (NSCLC). Here, we review perspectives of biomarker-driven personalized therapy in NSCLC, with particular reference to the detection of EML4-ALK gene rearrangements. Different molecular assays, validation, and clinical application to different types of tissue specimens are discussed.

AB - The development of molecular markers is crucial for improving therapy in advanced non-small cell lung cancer (NSCLC). Here, we review perspectives of biomarker-driven personalized therapy in NSCLC, with particular reference to the detection of EML4-ALK gene rearrangements. Different molecular assays, validation, and clinical application to different types of tissue specimens are discussed.

UR - http://www.scopus.com/inward/record.url?scp=77958072139&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=77958072139&partnerID=8YFLogxK

U2 - 10.1158/1078-0432.CCR-10-2005

DO - 10.1158/1078-0432.CCR-10-2005

M3 - Article

C2 - 20926402

AN - SCOPUS:77958072139

VL - 16

SP - 4909

EP - 4911

JO - Clinical Cancer Research

JF - Clinical Cancer Research

SN - 1078-0432

IS - 20

ER -